Nanoparticle-based vaccines trigger Th1-dependent humoral and cellular immune responses to treat or prevent infectious and non infectious diseases

BIANCHI DAIANA; CHAVERO CAMILA; RIZZO, GASTÓN; APUZZO EUGENIA; HERRERA SANTIAGO; AGAZZI MAXIMILIANO; CORTEZ LORENA; MARMISOLLE WALDEMAR; AZZARONI OMAR; SMALDINI, PAOLA LORENA; DOCENA GUILLERMO

Congreso; Reunión anual de Sociedades de Biociencias, Sociedad Argentina de Inmunología; 2022

Nanoparticle-based vaccines are used as novel immunointervention strategies to prevent or treat infectious and non-infectious diseases through the induction of T-dependent humoral and cellular effector mechanisms. We aimed to optimize a vaccination strategy and compare nanoparticles (Np) with other commonly used adjuvants. BALB/c mice were intraperitoneally administered with Np, Alum and Alum-CpG, and different concentrations of OVA as immunogen. The humoral (IgG, IgG1, IgG2a) and cellular immune responses were evaluated by ELISA and Flow Cytometry, respectively. Different control groups that received only the adjuvant or immunogen were included. We observed that Np triggered higher OVA-specific IgG antibodies in serum and bronchoalveolar lavage (BAL) than alum-based adjuvants (p